Raport.

MILESTONE MEDICAL INC. (11/2017) The change in the position of Chief Executive Officer

The Board of Directors of Milestone Medical Inc. (the „Company”, the „Issuer”) announces that the Board of Directors on July 10, 2017 adopted the resolution on the appointment of Mr. Daniel Goldberger for the position of Chief Executive Officer. Mr. Leonard Osser resigned from the position of Chief Executive Officer and Member of the Board of Directors effective as of the end of the day of July 10, 2017.
According to the best knowledge of the Board of Directors of Issuer, Mr. Goldberger does not perform the activities outside the Issuer, where such activities are significant for the Issuer.
Moreover, according to the best knowledge of the Board of Directors of Issuer, Mr. Goldberger:
- is not a partner in a competitive civil partnership or commercial law company
- is not a member of a body of competitive a joint-stock company
- is not a member of a body of any competitive legal person
- has no record in the register of insolvent debtors.
The personal form of Mr. Goldberger has been attached to this report.
Legal basis: Section 3.1.7 of the Exhibit 3 to the Alternative Trading System Rules “Current and Periodical Information in the Alternative Trading System on the NewConnect Market”.

Lista plików:

  • Załącznik nr: 1

    Pobierz plik
  • PERSONAL FORM
    DANIEL GOLDBERGER – CHIEF EXECUTIVE OFFICER
    (for members of Management and Supervisory Board )
    a) First name and surname, position or functions at the issuer, and term of office expiry
    date:
    None
    …………………………………………………………………………………………………………………………………………………….
    b) Description of qualifications and professional experience:
    Mr. Goldberger is a seasoned senior executive, consultant and board member with 35 years of
    life sciences and medical device experience , including sales, commercial scaling, supply chain,
    and business analytics. Mr. Goldberger has held senior leadership and board of directors
    positions at medical technology companies including Xtant Medical Holdings, Sound Surgical
    Technologies/Solta Medi cal, Xcorporeal, and Glucon. As CEO of Xtant, he oversaw a tripling of
    sales from $30 million to $90 million over a three and one -half year period. He also guided Xtant
    through a period of improved profitability and substantially increased enterprise value . With
    Sound Surgical, he boosted revenue from $9 million to $40 million over six years through a
    strategic restructuring and new product development. Dan holds a BS in Mechanical Engineering
    from MIT and an MS in Mechanical Engineering from Stanford Unive rsity.
    …………………………………………………………………………………………………………………………………………………….
    c) Information about activities performed by the person outside the Issuer where such
    activities are significant for the Issuer:
    None
    …………………………………………………………………………………………………………………………………………………….
    d) Information about all commercial law companies and partnerships in which, within at
    least the last three years, the person was a member of managing or supervisory bodies or
    a partner, indicating whether the person still performs functions on such bodie s or is still
    a partner:
    2013 –2017 – XTANT MEDICAL HOLDINGS, INC. (NYSE: XTNT) – CEO & Director
    2007 –2013 – SOUND SURGICAL TECHNOLOGIES – CEO & Director;
    2006 –2008 – XCORPOREAL, INC (AMEX:XCR) –President & CEO;
    2004 –2007 – GLUCON, INC – CEO & Director;
    2001 – 2004 – MEDICAL GROUP OF OSI SYSTEMS –President & Director;
    1996 – 2001 – OPTISCAN BIOMEDICAL – President & Director;
    …………………………………………………………………………………………………………………………………………………….
    e) Information about legally valid court decisions condemning the person for the crime of
    fraud within at least the last five years and indicating whether the person has been
    prohibited by the court to act as a member of managing or supervisory bodies in
    commercial law companies and partnerships within at least the l ast five years:
    None


    …………………………………………………………………………………………………………………………………………………….
    f) Details of all cases of bankruptcy, compulsory administration or liquidation, within at
    least the last five years, for entities in which the person was a member of managing o r
    supervisory bodies:
    None
    …………………………………………………………………………………………………………………………………………………….
    g) Information whether the person performs activities competitive to the activities of the
    Issuer or is a partner in a competitive civil partnership or commercial law comp any or
    partnership or a member of a body of a joint -stock company or a member of a body of any
    competitive legal person:
    None
    …………………………………………………………………………………………………………………………………………………….
    h) Information whether the person has a record in the register of insolvent debtors:
    None
    …………………………………………………………………………………………………………………………………………………….


    Treść w podglądzie może zawierać błędy powstałe podczas konwersji plików pdf.

Źródło: strona internetowa spółki, relacje inwestorskie, raporty bieżące i okresowe.

Oceń raport:


Pozytywny

Neutralny

Negatywny

WSZYSTKIE KOMUNIKATY SPÓŁKI
Informacje o spółce
Nazwa:Milestone Medical Inc.
ISIN:USU6005B1045
NIP:275484393
EKD:
Adres: 220 South Orange Avenue 07039 Livingston, Stany Zjednoczone
Telefon:0119735352717
www:www.medicalmilestone.com
Komentarze o spółce Milestone Medical ...
2018-07-22 11-07-33
iGPW
Nikt jeszcze nie skomentował tej spółki,
możesz być pierwszy.
Odpowiedzialność
prawna

Zgłoś moderatorowi
Copyright © 2017 iGPW
PiriBit Sebastian Urbański
ul. Okopowa 113/19 p.1
91-849 Łódź
NIP: 888-28-35-649